News coverage about CryoLife (NYSE:CRY) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CryoLife earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 48.0670900807073 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- BRIEF-Cryolife Says On Dec 1 Co Entered Into A Credit And Guaranty Agreement (CRY) (markets.businessinsider.com)
- Heart Valve Devices Market 2017 : Global Size, Share, Trends, growth and Forecast to 2025 – Acute Market Reports (menafn.com)
- CryoLife Completes Acquisition of JOTEC (finance.yahoo.com)
- CryoLife, Inc. (CRY) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
CryoLife (CRY) traded down $0.55 on Friday, hitting $19.80. The stock had a trading volume of 162,760 shares, compared to its average volume of 110,526. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. CryoLife has a twelve month low of $14.02 and a twelve month high of $24.00. The firm has a market capitalization of $662.47, a PE ratio of 48.29 and a beta of 0.81.
CRY has been the topic of a number of analyst reports. Lake Street Capital raised their price target on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday, October 11th. TheStreet cut CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research cut CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Northland Securities restated a “buy” rating and issued a $23.50 price target on shares of CryoLife in a research note on Monday, November 13th. Finally, Canaccord Genuity restated a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research note on Monday, October 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $23.63.
In related news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $19.63, for a total value of $392,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the transaction, the chief accounting officer now owns 98,705 shares in the company, valued at approximately $1,875,395. The disclosure for this sale can be found here. Insiders have sold 229,240 shares of company stock worth $4,888,065 in the last quarter. Insiders own 6.00% of the company’s stock.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.